PIK3CA and neoplasm: Nakayama et al., evaluating the significance of RAS/PIK3CA/BRAF tumor mutations in patients receiving first-line BV-containing treatment, showed that mutant-type tumors have a lower objective response rate (ORR) respect to wild-type tumors and that these differences are greater when considering only KRAS exon 2 mutations rather than all RAS (KRAS and NRAS)/PIK3CA/BRAF mutations.